New Mesothelioma Immunotherapy Option Introduced at Lung Cancer Conference, According to Surviving Mesothelioma

Share Article

Researchers in the Netherlands tell their colleagues that this monoclonal antibody could extend mesothelioma survival with minimal serious side effects.

Scientists Present Findings of New Mesothelioma Drug

New Immunotherapy Drug Shows Promise

We detected mild toxicity, long lasting results, and...a clear correlation between PD-L1 expression and response.

A paper presented at the recent World Lung Cancer Conference in Vienna, Austria suggests that nivolumab, a PD-1 blocker, may offer an alternative treatment strategy for mesothelioma patients previously treated with chemotherapy. Surviving Mesothelioma has just posted an article on the new report. Click here to read it now.

The Amsterdam-based scientists treated 38 malignant pleural mesothelioma patients with 3 mg/kg of nivolumab for two weeks.

“Nivolumab in second or later lines in recurrent malignant pleural mesothelioma met the primary endpoint,” study author Paul Baas, MD, PhD, said in a statement. “We detected mild toxicity, long lasting results, and we observed a clear correlation between PD-L1 expression and response.”

PD-L1 is a cell surface protein believed to be expressed in as many as 40 percent of mesothelioma tumors.

“Immunotherapy is widely believed to be one of the most promising treatment approaches for intractable cancers like mesothelioma,” says Alex Strauss, Managing Editor for Surviving Mesothelioma. “This study gives us another drug, along with pembrolizumab (Keytruda) and avelumab, to follow as it is further tested.”

To read more details of the nivolumab study and learn about other possible new mesothelioma immunotherapy drugs, see Immunotherapy Drug May Be New Option for Recurrent Mesothelioma, new available on the Surviving Mesothelioma website.

“Nivolumab Shows Promise in Treating Malignant Pleural Mesothelioma”, International Association for the Study of Lung Cancer, News Release, December 7, 2016,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website